RIO DE JANEIRO, (Reuters) - Brazilian researchers said yesterday the COVID-19 vaccine developed by China’s Sinovac Biotech is more than 50% effective based on trial data, but again withheld full results at the company’s request, raising questions about transparency.
The article Brazil institute says CoronaVac efficacy above 50%, but delays full results appeared first on Stabroek News.
